Divergent activation of the RXFP1 relaxin receptor by protein and small-molecule agonists

Publication information:

James Osei-Owusu, Tristan Girbau, Xunan Wang, Jeffrey S. Smith, Pengxiang Shen, Sarah C. Erlandson, Amanda K. Williamson, Xiaojing Cong, Mark W. Grinstaff, Daniel E. Kahne, Cherine Bechara, and Andrew C. Kruse. 2026. “Divergent Activation of the RXFP1 Relaxin Receptor by Protein and Small-Molecule Agonists”. Science, 394, Pp. eaei0135. doi:10.1126/science.aei0135

Abstract

The relaxin receptor RXFP1 is a therapeutic target owing to its potential benefits in the treatment of fibrosis and heart failure. Protein and small-molecule agonists are currently in midstage clinical trials for various forms of heart disease. In this work, we present three cryo–electron microscopy structures of RXFP1: ligand-free, bound to the native agonist relaxin-2, and bound to the small-molecule drug candidate AZD5462. These structures reveal that relaxin-2 engages the receptor’s ectodomain, whereas AZD5462 binds to the transmembrane domain. Together with hydrogen-deuterium exchange mass spectrometry, we show that relaxin-2 induces reorganization of the linker domain into a helical secondary structure. By contrast, AZD5462 stabilizes an active conformation through a distinct set of conformational rearrangements. Altogether, our findings define divergent activation mechanisms for protein and small-molecule agonists of RXFP1. The relaxin receptor is a high-profile drug target for diseases including heart failure, and several molecules are now in clinical trials. However, the mechanistic basis for activation of this multidomain G protein–coupled receptor has so far been unclear. Osei-Owusu et al. determined the cryo–electron microscopy structures of the relaxin receptor RXFP1 in the apo form bound to the native peptide agonist relaxin-2 and to a small-molecule agonist. Consistent with biochemical data, the authors found that the ligands had distinct binding sites, with the small molecule binding to the transmembrane region of the protein rather than to the extracellular domain. Along with very different binding interfaces, the activation mechanism appears to differ substantially, which may pose opportunities—but also challenges—for the further improvement of drugs and for targeting other receptors with similar architecture. —Michael A. Funk